Can Weight Loss Drugs Slow Aging? CO₂ Batteries Emerge as a New Energy Storage Concept

Weight Loss Drugs' Unexpected Benefit: Slowing Biological Aging

The capabilities of popular weight loss drugs may extend well beyond helping people shed pounds. Pharmaceutical companies have signaled that these medications could also hold potential for slowing the aging process. Eli Lilly and other drugmakers have indicated that these widely used weight loss drugs are showing promising signs at the biological aging level.

If validated further, this finding would significantly expand the application horizon for this class of drugs. Weight loss medications have traditionally been valued for controlling body weight and improving metabolic markers. But if they can genuinely act on the underlying mechanisms of biological aging, their potential health benefits could extend to a much broader range of age-related diseases. That said, current conclusions are primarily based on statements from pharmaceutical companies, and more rigorous, independent clinical research will be needed to confirm their scientific validity.

Why This Direction Is Worth Watching

Biological aging is a shared risk factor for many chronic diseases. If a drug already widely on the market — with a relatively well-established safety profile — can also slow aging as a side benefit, the public health implications would be significant. But readers should remain measured in their expectations: there is still a considerable gap between early signals from drug companies and peer-reviewed, definitive evidence. Until results from large-scale, long-term studies are published, any claims about "anti-aging" effects should be treated with caution.

The mechanistic hypothesis behind weight loss drugs slowing aging centers on GLP-1 receptor agonists (such as semaglutide and tirzepatide). These drugs were originally developed for type 2 diabetes and later gained widespread use for obesity due to their pronounced weight loss effects. GLP-1 (glucagon-like peptide-1) is a gut-secreted hormone that stimulates insulin secretion, suppresses appetite, and delivers protective signals to multiple organs. Researchers have found that beyond metabolic regulation, this class of drugs also exhibits anti-inflammatory properties and reduces oxidative stress — and chronic inflammation alongside oxidative damage are core drivers of accelerated aging, a phenomenon known as "inflammaging." Some animal studies and observational data also suggest an association between GLP-1 receptor agonist use and reductions in cardiovascular events and improvements in kidney health, both of which are aging-related conditions. However, a significant mechanistic gap remains between metabolic benefits and genuine aging delay at the level of the "biological clock."

CO₂ Batteries: A New Approach to Energy Storage

Beyond pharmaceutical advances, this tech briefing also highlights a development in energy technology — the CO₂ battery. Using carbon dioxide as an energy storage medium is one of the clean energy approaches that has attracted growing exploration in recent years. The basic idea is to store and release energy by leveraging CO₂ transitions between different states, offering a potential alternative pathway for grid-scale energy storage.

As the share of renewable energy continues to rise, long-duration energy storage has become a critical bottleneck for stable grid operation. While lithium-ion batteries are mature technology, they face limitations in cost, resource availability, and performance in ultra-long-duration storage scenarios. CO₂ batteries and similar novel storage technologies are receiving sustained attention from researchers and industry players against this backdrop.

The core principle of CO₂ batteries involves using phase transitions of CO₂ between liquid and gaseous states, or electrochemically reducing CO₂ into carbonates and similar compounds to store energy, then reversing the process during discharge. Unlike the electrochemical storage of lithium-ion batteries, some CO₂ storage approaches are closer to "thermodynamic storage" — analogous to pumped hydro, but using CO₂ as the working fluid. Their potential advantages include the abundance and low cost of CO₂ as a feedstock, and the fact that some schemes can directly utilize CO₂ from industrial emissions, delivering the dual benefit of carbon capture and energy storage. Representative approaches include the "CO₂ dome" system being developed by companies such as Energy Dome, which liquefies CO₂ for storage at ambient pressure, then vaporizes it on demand to drive turbines and generate electricity. The main challenges facing this technology today are system efficiency (round-trip efficiency of around 75%) and the cost validation of large-scale engineering deployment — it has yet to reach the commercial maturity of lithium-ion batteries or pumped hydro.

The Common Logic Behind Both Technology Trends

Whether it's the unexpected anti-aging potential of weight loss drugs or the exploration of CO₂ batteries for energy storage, both developments reflect a shared theme in today's technological progress: existing technologies and products are being reexamined to uncover value beyond their original design objectives. This kind of "one thing, multiple uses" or "old roads, new directions" thinking often unlocks breakthrough application opportunities.

Of course, these early-stage developments will need time to be validated. For readers following the technology frontier, staying curious while maintaining healthy skepticism — and waiting for more comprehensive data and real-world verification — remains the wisest approach.

Note: This article is based on content from the tech newsletter The Download. The original information is relatively brief, and some conclusions await further research confirmation.